For VA Investigators
March 15, 2006 VA will began to transition from Clinical Trial Agreements (CTAs) [or Clinical Research Agreement (CRAs)] to Cooperative Research and Development Agreements (CRADAs) to establish terms of collaborations with industry research sponsors. This change will be largely invisible to you the Principal Investigator. However, CRADAs have a number of advantages over CTAs and these include:
- Protection of background inventions, trade secrets and confidential information
- Establishment of intellectual property ownership and licensing options in advance of an invention
- Protection and management of intellectual property developed by dually appointed, VA/university, personnel (DAPs)
- Increased interactions between the federal government, universities, foundations and industries.
- Collaboration with non-federal partner to makes available, complete or partial, funding support
- Stronger protection for PI initiated studies
Selected key features of CRADAs:
- Government may provide personnel, services, facilities, equipment or other resources but not funds
- Collaborator may provide funds, personnel, services, facilities, equipment or other resources
- Others
|